Samsung Biologics Co.,Ltd.
207940
Rang in Aktien
#498
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon,... Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
Aktienkurs
$1,028.49
Marktkapitalisierung
$47.88B
Veränderung (1 Tag)
-3.67%
Veränderung (1 Jahr)
-18.37%
Land
KR
Handel Samsung Biologics Co.,Ltd. (207940)
Kategorie
Healthcare
Kursverlauf für Samsung Biologics Co.,Ltd. (207940)
Höchster Schlusskurs: $917.33 am 2026-10-01
Niedrigster Schlusskurs: $215.60 am 2016-11-01
Niedrigster Schlusskurs: $215.60 am 2016-11-01
Kursverlauf der Aktie von Samsung Biologics Co.,Ltd. von 2016 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | -6.12% |
| 2025 | 12.74% |
| 2024 | 21.95% |
| 2023 | -14.64% |
| 2022 | -16.07% |
| 2021 | 2.83% |
| 2020 | 117.47% |
| 2019 | 6.18% |
| 2018 | -1.56% |
| 2017 | 164.22% |
| 2016 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
